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SUMMARY OF ABBREVIATIONS USED IN THIS THESIS 
 
Abbreviation    Definition 
ATA    Atmospheres absolute = the pressure relative to a vacuum 
    (1 ATA = 101.3 kilopascals) 
CI    Confidence interval (statistical) 
CNS    Central nervous system 
CO offgassing Process of carbon monoxide being excreted in the breath as it is 
eliminated from the body 
CO    Carbon monoxide 
COHb    Carboxyhaemoglobin 
COHb% Carboxyhaemoglobin percent = the amount of carbon monoxide 
bound to haemoglobin, expressed as a percentage of total 
haemoglobin 
CONSB    Carbon monoxide neuropsychiatric screening battery.  
    A series of psychometric tests to measure cognitive function. 
DCI Decompression illness = a syndrome caused by the formation of 
nitrogen bubbles in the body of a diver after decompression from 
exposure to compressed air 
DNS Delayed neurological syndrome = a syndrome of delayed 
deterioration in neurological or cognitive function occurring 3-40 
days after apparent recovery with acute treatment 
ECG    Electrocardiogram = measurement of the electrical activity of the  
    heart using skin electrodes 
ED    Emergency department 
ECO Mean expired carbon monoxide concentration, expressed in parts 
per million  
 VII 
FIO2   Fraction of concentration of inspired oxygen, expressed as 
decimal 0 - 1.0, indicating of the relative amount of oxygen in the 
total inspired gas 
FSQ    Functional status questionnaire 
GCS  Glasgow coma score (scale 3-15) = description of conscious state 
Detailed in appendix 18.2.1 
GHQ-12    General health questionnaire (12 questions) 
Hb    Haemoglobin 
HBO    Hyperbaric oxygen 
HBOT    Hyperbaric oxygen treatment or hyperbaric oxygen therapy 
HMF    Higher mental function 
LOC    Loss of consciousness 
LPG    Liquid propane gas 
Min    Minute 
MMSE Mini-Mental State Examination.  A cognitive function test 
with a score from 0 to 30. Detailed in appendix 18.2.2. 
NBO  Normobaric oxygen = 100% oxygen breathed at ambient 
atmospheric pressure (Usually 101.3 kPa) 
NNT Number needed to treat. The number needed to treat using a 
therapeutic modality to gain one extra good outcome 
O2    Oxygen 
P    Pressure 
PAO2    Alveolar oxygen partial pressure  
PaO2    Arterial oxygen pressure 
 VIII 
PIO2 Pressure of inspired oxygen = the partial pressure of the  
inspired oxygen 
 PNS Persistent neurological sequelae = persistent neurological or 
cognitive deficits after treatment for acute CO poisoning 
ppm    Parts per million  
PSIg  Pounds per square inch gauge pressure = the measured pressure in 
PSI, which is above ambient pressure 
RMV  Respiratory minute volume = the amount of breath exhaled in one 
minute (litres)  
SD    Standard deviation (statistical) 
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2. THESIS ABSTRACT 
 
Carbon monoxide (CO) is a colourless, odourless toxic gas that is able to substitute for oxygen at 
many levels in the oxygen cascade. CO poisoning is responsible for nearly a quarter of suicide deaths 
in Australia, and hundreds of individuals sustain non-fatal poisoning every year. Up to two thirds of 
individuals who survive CO poisoning have long-term neurological or cognitive impairment. Despite 
years of study by medical researchers, a reliable marker of acute CO poisoning severity that correlates 
with outcome has not been identified. Oxygen is known to be an antidote to CO poisoning, yet there is 
significant debate regarding the dose required, and the treatment duration. The end-point of CO 
excretion from the body is the lungs. Measurement of expired CO has been documented since the 
1980’s, however there has been limited study of ECO in poisoned patients. 
In this research ECO was investigated as marker of CO poisoning, and its application in determining 
treatment end-point. A low cost, portable and non-invasive apparatus was successfully developed for 
measurement of ECO, oxygen concentration and minute volume. The apparatus was then evaluated in 
a variety of settings, for adults and children, and to establish baseline ranges for non-smokers, smokers 
and poisoned individuals, breathing air, NBO and HBO. The technique of measuring ECO was further 
investigated to determine the relationship between ECO and COHb, and for the diagnosis of CO 
poisoning. The apparatus was evaluated in the clinical setting to determine pulmonary CO elimination 
kinetics. A prospective series of CO poisoned patients was enrolled to determine if acute ECO levels 
correlated with clinical outcomes and to assess whether unrecordable ECO was a suitable marker of 
treatment end-point. In this research, expired oxygen concentration was also monitored, to ensure that 
all individuals received the stated dose of oxygen. 
Baseline levels of ECO were found to be very low in healthy non-smoking volunteers, and in non-
smoking divers treated for decompression illness, consistent with the observation that most CO derives 
from exogenous sources. Smokers had higher baseline ECO than non-smokers, and smoker ECO 
levels correlated positively with the number of cigarettes smoked per day, and negatively with the time 
since last cigarette.  
Breathing air and NBO, a strong positive linear relationship between the ECO and COHb was 
observed for non-poisoned smokers, poisoned individuals and pooled data. Expired CO concentration 
increased in proportion with increasing FIO2 for 0.21 (air) to 1.0 (NBO). While breathing 100% oxygen, 
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increasing ambient pressure from 1 ATA to 2.8ATA did not alter the ECO concentration (ppm) in each breath. 
However, elimination of CO was greatly enhanced due to the increased density of gas at higher pressures. Each tidal 
volume at 2.8ATA actually contains 2.8 times as many molecules of CO compared with the same tidal volume at 
1ATA ambient pressure.  When poisoned subjects breathed NBO and HBO, significant amounts of ECO 
were detectable when the COHb was unrecordable using the biochemical method.  This suggested that 
ECO more accurately reflected remaining CO in body stores than COHb, however this might have 
resulted from the limits of the biochemical method for detecting low levels of COHb (< 2%).  
Concurrent measurement of expired oxygen provided useful confirmation that the intended 100% 
oxygen dose was delivered to all treated individuals. 
ECO was a useful non-invasive test to diagnose acute (< 6 hours) CO poisoning, when ECO values 
were > 40 ppm. For ECO values of 7 ppm to 40 ppm, clinical information would be needed to separate 
mildly poisoned individuals from smokers. Expired CO and COHb were equally effective in 
identifying acutely poisoned individuals, from smokers and non-smokers. Critical values of ECO >40 
ppm or COHb > 7% were shown to be highly specific for CO poisoning.  
Expired CO demonstrated single stage exponential elimination kinetics in both NBO and HBO 
treatment environments. CO elimination in HBO was significantly faster than NBO. There was a seven 
to ten-fold variation in CO elimination between individuals in either treatment (NBO or HBO). Based 
on these findings, current empirical regimens may over-treat some individuals and under-treat others. 
The half-lives determined for ECO elimination were longer than those determined for COHb. This 
suggests that elimination of CO via the breath may be slower than elimination from Hb. If 
unrecordable ECO proved useful as a treatment endpoint, this would allow treatment to be tailored to 
the individual’s acute CO load. 
In the clinical series of 66 acutely poisoned patients, there were a high number of males sustaining CO 
poisoning from deliberate self-harm. These individuals had longer exposures, greater neurological 
toxicity, and were more likely to have LOC than accidental exposures. The greater toxic effect and 
higher CO body load was most likely due to breathing leaded petrol exhaust containing high CO levels 
to attempt suicide. In keeping with their greater neurological toxicity, there was a positive correlation 
between ECO, COHb levels, and the severity of poisoning. The ECO measurement breathing oxygen 
correlated significantly with the severity of neurological impairment in the ED. This provided support 
for ECO levels as useful guide to acute clinical poisoning severity. However, acute ECO and COHb 
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levels measured in the ED were not predictive of outcome at 3 months. This may have been affected 
by significant delays in transferring patients for HBO treatment.  
Just over 28% of patients had poor outcomes at 3 months, using unrecordable ECO as a treatment end-
point. At this point, patients who had abnormal neurological or cognitive function remained abnormal 
at 3 months. Unfortunately the treatment endpoint using ECO did not prevent cases of DNS, or the 
need to provide follow-up for CO poisoned patients. The occurrence of DNS after all CO had been 
removed suggests that DNS may result from mechanisms other than direct CO toxicity.  
Poor outcomes were associated with delays to study entry, suicide attempts, motor vehicle exhaust as a 
source of CO and acidosis measured in the ED. Individuals with LOC did not have a significantly 
worse outcome than those remaining conscious during their CO exposure. HBO and NBO treated 
patients had similar levels of PNS, however the HBO group had a lower incidence of DNS – an 
unexpected finding. Because the study was not randomized, it was not possible to conclude this is a 
definite treatment effect. Compared with NBO, HBO treatment led to faster removal of CO, and 
shorter treatments. 
Measurement of ECO constitutes a novel non-invasive method of monitoring of acute CO poisoning. It 
has potential to compliment existing methods of monitoring acute CO poisoning, and may be useful as 
a non-invasive test to diagnose CO poisoning.  Clinical outcomes in this series compared favourably 
with other series of similar severity poisoning in the literature. However, further research using a 
randomized controlled trial is required to determine if unrecordable ECO is a useful guide to treatment 
endpoint. 
 
